122 results about "Cellular infiltration" patented technology

Provided herein are methods for treating gastrointestinal inflammation, for example, esophageal inflammation, or reduction of eosinophilic infiltration of the esophagus and / or reducing local and systemic exposure and / or side effects resulting therefrom. Provided herein are methods for diagnosing gastrointestinal inflammation, for example, esophageal inflammation, or reduction of eosinophilic infiltration of the esophagus. Also provided herein are methods for inducing remission of eosinophilic infiltration of the esophagus

Methods and compositions using E-selectin antagonists are provided for the treatment and prevention of diseases and disorders treatable by inhibiting binding of E-selectin to an E-selectin ligand. Described herein are E-selectin antagonists including, for example, glycomimetic compounds, antibodies, aptamers and peptides that are useful in methods for treatment of cancers, and treatment and prevention of metastasis, inhibiting infiltration of the cancer cells into bone marrow, reducing or inhibiting adhesion of the cancer cells to endothelial cells including cells in bone marrow, and inhibiting thrombus formation.

Aporous composite fibrous scaffold for repair or regeneration of bone is disclosed. The scaffold comprises a first biopolymer forming a porous matrix and a second biopolymer forming fiber reinforcement. The biocompatible scaffold is configured to maintain balance between porosity and mechanical strength which could aid cellular infiltration and bone tissue regeneration. A method of preparing the porous composite scaffold is also disclosed.

A hierarchical multiscale fibrous scaffold comprises multiple patterned layers of microfibers with one or more layers of nanofibers interleaved therebetween. In a method for making such scaffolds, electrodeposition or near-field electrospinning is used to deposit patterned layers of microfibers in a stack. Conventional electrospinning is used to deposit nanofibers on the layers of microfibers. The method may be used to tune the mechanical properties of the scaffold, facilitated by microfibers, and the biological features of the scaffold, facilitated by nanofibers. Scaffolds produced by such a process may have highly biomimetic architectures, and allow rapid cellular infiltration and sustainable cell growth for multiple tissue types.

Tissue engineering structures with biologically favorable structural and chemical properties are disclosed. More particularly, the present disclosure is directed to tissue engineered scaffolds having a fiber support and honey. The tissue engineered scaffolds having a fiber support and honey can further include at least one biomolecule. The tissue engineered scaffolds can be used to promote cellular chemotaxis, enhance cell proliferation, enhance extracellular matrix production, increase angiogenesis, and provide antimicrobial activity. The nature of the tissue engineered scaffolds provides a template for cellular infiltration and guide tissue regeneration. The tissue engineered scaffolds can be used in the treatment of dermal wounds (burns, chronic wounds, etc.) or as a tissue engineering scaffold in a wide range of applications.

A process for the preparation of a tissue matrix suitable for regenerative repair of tissues, including contacting an isolated connective tissue with an amount of detergent and an amount of disinfectant to significantly reduce at least one of lipids, phospholipids, nucleic acids, major histocompatibility (MHC) antigens, contaminating microorganisms, and endotoxins. The process further provides for less significant reduction in proteoglycan content while retaining the overall structure of the tissue matrix produced. Processing may further include micronizing the tissue matrix. Also, a tissue matrix having a scaffold portion and non-structural portion, collectively structured to promote cellular infiltration, attachment, and proliferation. The tissue matrix may be in the form of a sheet, thick sheet, or micronized. Also, kits including a prepared tissue matrix for use in regenerative repair, and kits for preparing a tissue matrix.

The invention belongs to the field of immunological therapy and in particular relates to a transformed hinge region and application thereof in construction of a CAR skeleton. The hinge region providedby the invention can prolong in vivo existence of CAR-T cells and / or improve capability of the CAR-T cells for infiltrating tumors, and an amino acid sequence of the hinge region is shown in SEQ ID NO.1 and SEQ ID NO.2. The hinged region structure provided by the invention can prolong the in vivo existence of the CAR-T cells, a combined chimeric antigen receptor of the hinged region structure canbe more stably expressed in T lymphocytes, CAR-T containing the hinged region provided by the invention is longer in vivo existence, the capability of the cells for infiltrating the tumors is obviously enhanced, and killing effect is better.

Provided is a collagen structure characterized by: comprising collagen fibers of 1 to 5 µm in average diameter; and has a water content of 0 to 15 (w / w)% and a collagen density of 50 to 800 mg / cm 3 . After generating collagen fibers by neutralizing an acidic collagen solution, the resulting solution is subjected to filtration or the like to form crude collagen fibers having a collagen concentration of 12 to 50 (w / v)%. The thus obtained crude collagen fibers are molded into a prescribed shape and then dried, thereby the collagen structure can be produced. Since the collagen structure is produced using, as raw material, collagen fibers that are formed by association of collagen molecules, the collagen structure has excellent cell infiltration property. Further, since the collagen density of the collagen structure is equivalent to that of in vivo collagen tissue, the collagen structure exhibits excellent tissue regeneration capacity when filled into a defective part in vivo. Therefore, the collagen structure can be preferably used as an artificial material for regenerative medicine and the like.

The invention relates to bifidobacterium longum capable of relieving atopic dermatitis and application thereof, and belongs to the technical field of microorganisms and the technical field of medicine. Bifidobacterium longum has the effect of relieving atopic dermatitis, and has the advantages that the ear swelling degree of a mouse with atopic dermatitis is remarkably decreased; dermal pathologysymptoms of the mouse with atopic dermatitis are relieved remarkably, and inflammatory cell infiltration is relieved; the serum IgE of the mouse with atopic dermatitis is reduced remarkably; the levelof IL-4 and IL-13 in skin tissue of the mouse with atopic dermatitis is decreased remarkably; the level of histamine in the skin tissue of the mouse with atopic dermatitis is decreased remarkably. Inthis way, bifidobacterium longum has broad application prospects in preparation of products for preventing and / or treating atopic dermatitis.

Disclosed is the use of an adhesion molecule inhibitor that is effective in the prevention and treatment of inflammatory diseases caused by infiltration of leukocytes such as monocytes, lymphocytes and eosindphils, by inhibiting cell infiltration which mediates adhesion molecules, especially adhesion molecule VLA-4. Since the spiro acid derivatives according to the present invention are excellent in the effect of inhibiting cell adhesion via adhesion molecules, especially adhesion molecule VLA-4, they are useful as therapeutic drugs against various inflammatory diseases. For example, provided are the spiro derivative and the adhesion molecule inhibitor which includes as an active ingredient the spiro derivative as shown by the below formula (18).

The present invention proposes a radiomics-based biomarker for detecting the presence and the density of tumor infiltrating CD8 T-cells in a solid tumor without having to use any biopsy of said tumor.The invention also proposes to use this information to assess the immune phenotype of said solid tumor. In a particular embodiment, the invention proposes to prognose the survival and / or the treatment efficiency of cancer patients treated with immunotherapy such as anti-PD-1 / PD- L1 monotherapy.

Described herein are MCAM antagonists, including MCAM antagonist antibodies capable of inhibiting the interaction between MCAM and it ligand, a laminin α4 chain, e.g., an α4 chain of laminin 411. These MCAM antagonists, e.g., anti-MCAM antibodies, may be useful to treat neuroinflammatory conditions, for example, multiple sclerosis and Parkinson's disease, by inhibiting the infiltration of MCAM-expressing cells into the central nervous system (CNS), e.g., extravasation of TH17 cells into the CNS.

The invention provides a biological tendon repairing material and a preparation method thereof. The biological tendon repairing material comprises an extracellular matrix body subjected to immunogen removal, wherein the extracellular matrix body consists of one or more layers and comprises a first surface and a second surface; the first surface comprises a first area and a second area; the mechanical strength of the first area is lower than that the second area. During preparation of an extracellular matrix subjected to immunogen removal, layering is avoided. As the biological tendon repairingmaterial is provided with the surface which consists of the first area and the second area, cellular infiltration of defective tissues is facilitated, tissue repairing is accomplished, stress born bythe repairing material can be uniformly distributed, and local stress cannot be excessively large. Besides, the surface has a high suture retention force and can serve as the second surface of a suture area of the repairing material, and the strength of the repairing material can be guaranteed while repairing of the defective tissues is facilitated.

The invention belongs to the technical field of traditional Chinese medicines and relates to oral liquid for treating chronic atrophic gastritis. The oral liquid is prepared by the following components in parts by weight: 10 parts of Zhejiang white atractylodes rhizome, 15 parts of poria cocos, 10 parts of orange peel, 10 parts of pinellia tenata breit, 10 parts of vinegar rhizoma cyperi, 10 parts of fructus amomi, 10 parts of mangnolia officinalis, 10 parts of vinegar curcuma aromatic, 15 parts of artemisia anomala, 6 parts of cassia twig, 10 parts of rhizoma corydalis, 10 parts of hawthorn, 10 parts of roasted malt, 10 parts of roasted medicated leaven, 10 parts of lindera aggregate, 15 parts of radix paeoniae alba, 12 parts of radix pseudostellariae and 3 parts of liquorice. The oral liquid provided by the invention has the effects of relieving inflammatory cell infiltration, regulating cellular immunity and humoral immunity function, restraining the activity of pepsinogen to promote proliferation and recovery thereof, strengthening barrier protection function of the mucosa, regulating gastrointestinal motility, increasing permeability of gastric mucosa, improving blood circulation of the mucosa, promoting atrophic glands to recover, and delaying or reversing progression of diseases.

The present invention is drawn to methods for measuring numbers, levels, and / or ratios of cells, such as lymphocytes, infiltrated into a solid tissue, such as a tumor or a tissue affected by an autoimmune disease, and to methods for making patient prognoses based on such measurements. In one aspect, methods of the invention comprise sorting lymphocytes from an accessible tissue, such as peripheral blood, into functional subsets, such as cytotoxic T cells and regulatory T cells, and generating clonotype profiles of each subset. An inaccessible disease-affected tissue is sampled and one or more clonotype profiles are generated. From the latter clonotype profiles, levels lymphocytes in each of the functional subsets are determined in the disease-affected tissue by their clonotypes, which are identified from lymphocytes sorted into subsets from the accessible tissue.

The invention belongs to the technical field of bioengineering, and particularly relates to a biological mixed artificial blood vessel, a preparation method thereof and an application of Sca-1<+> vascular stem cells in preparation of the biological mixed artificial blood vessel. The biological mixed artificial blood vessel is divided into an inner layer and an outer layer, an inner layer main bodyintravascular stent is prepared from a polymer material PCL through electrostatic spinning or through an acellular matrix method, heparinization is conducted on a blood vessel main body in a covalentbinding mode, cell infiltration and angiogenesis are facilitated, and the risk of thrombosis is reduced; and the outer layer is GelMA hydrogel encapsulating Sca-1<+> vascular stem cells, and the hydrogel has good cell adhesion, so that the cells are not easy to fall off. The artificial blood vessel can help blood vessel repair and promote endothelialization when the blood vessel is damaged. The Sca-1<+> vascular stem cells on the outer membrane are generally firstly activated, and the Sca-1<+> vascular stem cells differentiated into endothelial cells influence the structure and tension of thevascular wall and can participate in endothelial repair, vascular regeneration, immunoregulation and the like.

The invention belongs to the technical field of pharmacy. According to the application of a protein tyrosine phosphatase SHP2 inhibitor SHP099 in preparation of the medicine for treating psoriasis, aiming at an imiquimod-induced mouse psoriasis-like disease model, the SHP099 can effectively improve epidermal thickening of mouse skin lesion tissues, inflammatory cell infiltration and the level of inflammatory factors in mouse serum. At the cellular level, the SHP099 can significantly reduce the release of inflammatory factors related to psoriasis.

A compound represented by the following general formula (1) or (100), a salt thereof or a hydrate of the foregoing has excellent cell adhesion inhibitory action and cell infiltration inhibitory action. wherein R10 represents 5- to 10-membered cycloalkyl etc. optionally substituted with hydroxyl etc., R30, R31 and R32 may be the same or different and each represents hydrogen etc., R40 represents C1-10 alkyl etc. optionally substituted with hydroxyl etc., n represents an integer of 0, 1 or 2, X1 represents CH or nitrogen, and R20, R21, R22 and R23 may be the same or different and each represents hydrogen etc.

The invention relates to a biomarker for gastric cancer diagnosis and treatment and prognosis evaluation, an application of the biomarker and a detection kit. Tumor infiltration immune cytokine IL23Ais used as the biomarker for the gastric cancer diagnosis and treatment and prognosis evaluation, and the relative expression level of the tumor infiltration immune cytokine IL23A is detected to evaluate the prognosis condition of patients. Compared with the prior art, the biomarker provided by the invention has the following advantages: cytokine of the biomarker participates in a plurality of immune response infiltrated by tumor immune cells, can realize the staged development stage of the risk of gastric cancer from a molecular level, rapidly and accurately detect and evaluate the prognosisof the gastric cancer, and effectively improve the sensitivity and specificity of prognosis detection and evaluation of the gastric cancer.

A stent composed by a bioabsorbable network of polymer fibers that can be rearranged upon expansion, accommodating for diameter enlargement without the need of a strut or strut pattern and providing temporary support to a biological duct, is provided. Additionally, a stent is provided where the rearranged fibrous network of its expanded state can act as a scaffold for cell infiltration and promote autologous tissue formation.

The invention provides an application of a 3-[[2-[3-oxo-(1, 2-benzisoxazole-6-yl) methoxyl]-5-[(2-hydroxyl-4-cyclopentoxyl benzoyl)] phenyl] propionic acid (compound I) in preparation for treatment of connexin CX31 mediated skin disease. The connexin CX31 mediated skin disease comprises erythrokeratodermia variabilis or psoriasis. The pharmacological experiment proves that a low-dose group and a high-dose group of the compound I can remarkably reduce skin damage degree of a psoriasis animal sample; the content of TNF-alpha in murine serum can be restrained by the low-dose group of the compound I, then inflammatory cell infiltration is restrained, the inflammatory response is relieved, and the compound I has good psoriasis treatment effect and can be used for treating the connexin CX31 mediated skin disease.

This invention relates to polysaccharide materials and more particularly to microbial-derived cellulose having the porosity and containing pores of the desired size making it suitable for cellular infiltration during implantation and other desirable properties for medical and surgical applications. The invention also relates to the use of porous microbial-derived cellulose as tissue engineering matrices, human tissue substitutes, and reinforcing scaffolds for regenerating injured tissues and augmenting surgical procedures. The invention outlines various methods during and after fermentation to create porous microbial cellulose capable of allowing cell infiltration while preserving the physical properties of the microbial-cellulose.

A stent composed by a bioabsorbable network of polymer fibers that can be rearranged upon expansion, accommodating for diameter enlargement without the need of a strut or strut pattern and providing temporary support to a biological duct, is provided. Additionally, a stent is provided where the rearranged fibrous network of its expanded state can act as a scaffold for cell infiltration and promote autologous tissue formation.

The invention provides an externally applied gel for treating gout, which is an externally applied medicine made from traditional Chinese medicine components such as nidus vespae, colchicine, a gel matrix, and the like., and by taking a coupling medium as transdermal carrier. The anti-gout gel can quickly eliminate redness, swelling, pain and fever symptoms of gouty arthritis, inhibit granulocyte infiltration and formation of lactic acid, reduce synthesis of uric acid, shorten and stop the acute attack of the gouty arthritis, prevent gout complications that threaten life, suspend tissue and organ damage caused by deposition of the uric acid, thus ensure that the illness of a patient is stabilized and can not deteriorate anymore for a long time. With the coupling medium adopted as the transdermal carrier of the medicine, the gel is characterized in that: a dermal hydration gradient can be naturally formed in the skin permeation course of the coupling medium, the gradient is independent of concentration when driving osmotic pressure difference, the gel has high deformability, can keep the components thereof unchanged after the skin permeation course and can permeate corneum of mammals through a plurality of transformation. The gel also has high transdermal efficiency, and full dermal permeabilities are not different between species and different parts. The gel avoids the deficiencies of injections and oral liquid medicines, is safe owing to the external use, and has no toxicity and side effects. The gel has simple components, low cost, requires no special devices and production conditions, and is available for large-scale industrialized production.

Methods to inhibit inflammation and macrophage infiltration following spinal cord injury are disclosed along with methods to modulate TNFalpha release from cells expressing alphad are disclosed.

The invention discloses an application of minocycline hydrochloride to preparation of a medicine for treating autoimmune uveitis and a treatment method of the autoimmune uveitis. The inventor finds that the minocycline hydrochloride can be used as an early intervention medicine by exploring the treatment effect of minocycline with different administration dosages on the autoimmune uveitis. By inhibiting microglial cell activation of retina tissue, reducing immune cell infiltration and reconstructing a steady state in gastrointestinal tract flora, generation and development of the uveitis are effectively inhibited, a new application is provided for application of the minocycline hydrochloride, and besides, a new strategy and method are provided for early prevention and intervention of the autoimmune uveitis.

The invention provides an anti-rheumatoid arthritis human umbilical cord mesenchymal stem cell injection and a preparation method thereof. Every 100ml of the umbilical cord mesenchymal stem cell injection comprises: 4-6*10<5> human umbilical cord mesenchymal stem cells, 2-4g of human serum albumin, 10-30mg of Chinese yam polysaccharide, 60-90mg of compound amino acid, 0.5-0.6g of sodium chloride,0.5-0.6g of sodium gluconate, 0.3-0.4g of sodium acetate, 0.03-0.04g of potassium chloride and 0.03-0.04g of magnesium chloride. The human umbilical cord mesenchymal stem cell injection special for resisting rheumatoid arthritis prepared by the invention can effectively maintain the activity of umbilical cord mesenchymal stem cells, has good stability, also can effectively stop inflammatory mediator release, alleviates inflammatory cell infiltration degree, significantly reduces pannus number, and has good repair effect on rheumatoid arthritis bone and cartilage damage, thus having broad application prospects.

ACE receptors are affected in severe acute respiratory distress syndrome related coronaviruses. ACE genes are directly related to the morbidity and mortality of those with cystic fibrosis. The thick, sticky mucus in the respiratory, and digestive systems, is seen in the inherited disease cystic fibrosis. Viral induced sticky mucus in the respiratory and digestive systems can also be appreciated as a response to viral pathogens where the cycle of mucus production in vivo induces the recruitment of more mucus production to the extent that cellular damage occurs within the lower respiratory track requiring intubation as a life saving measure. In the most severe cases mechanical intubation fails due to the fact that no control over the recruitment of mucus production was achieved at the onset. SARS pathology shows inflammatory exudation in the alveoli and interstitial tissue, with hyperplasia of fibrous tissue and fibrosis. Inherited cystic fibrosis pathology shows atelectasis, mucoid impaction, acute and chronic inflammation, bronchiectasis, cyst formation, and fibrosis widespread. A virally induced disorder in relations to ACE2 receptors can be treated successfully at the early onset with inherited cystic fibrosis disease mimicking techniques with the efforts of minimizing the activity and utilization of the ACE2 receptor. Cystic fibrosis lung infections, and opportunistic pathogens contribute to chronic airway inflammation that is characterized by neutrophil / macrophage infiltration, cytokine release and ceramide accumulation. In terms of virally induced forms off ACE2 receptor pathologies, as it related to coronavirus such as Covid 19, presumably ceramide precursors which aid in intracellular transport of the virus into the cell via inflammation and remodeling is present in alveolar tissues of the lung in patients with cystic fibrosis while the same pathology occurs in patients with virally induced forms of ACE2 pathology which to often progresses to SARS or ARDS.